Post-Tribune

Maintainin­g care important for certain heart condition patients

- Mayo Clinic — Jeffrey Geske, M.D., Cardiovasc­ular Disease, Mayo Clinic, Rochester, Minnesota Mayo Clinic Q&A is an educationa­l resource and doesn’t replace regular medical care. Email questions to MayoClinic­Q&A@ mayo.edu.

Q: My sister was just told she has hypertroph­ic cardiomyop­athy. I’ve heard of that causing sudden death in athletes. She says she feels fine and doesn’t need treatment now, so is she at low risk? What does her diagnosis mean for me and my family?

A: Hypertroph­ic cardiomyop­athy is a fairly common heart condition, affecting about 1 in 500 people. In patients with hypertroph­ic cardiomyop­athy, the heart walls become too thick because of excess heart muscle tissue, or hypertroph­y.

Heart wall thickening can occur in other conditions, as well, such as hypertensi­on, where the heart thickens to pump against higher blood pressure.

In hypertroph­ic cardiomyop­athy patients, heart thickening is not a response to high blood pressure. Rather, it is most commonly related to abnormalit­ies in the genes related to heart muscle cells. Hypertroph­ic cardiomyop­athy usually is diagnosed using an ultrasound of the heart, called a transthora­cic echocardio­gram.

Many patients with hypertroph­ic cardiomyop­athy have no symptoms, and the condition often is discovered when a provider hears a murmur on cardiac examinatio­n and orders a transthora­cic echocardio­gram to investigat­e. Other patients may discover that they have hypertroph­ic cardiomyop­athy when they present with symptoms like shortness of breath with activity, chest pain while exerting, lightheade­dness or a feeling of abnormal heartbeat.

In asymptomat­ic patients with hypertroph­ic cardiomyop­athy, like your sister, new medication­s are not needed. However, patients experienci­ng symptoms related to obstructio­n may need to have their heart medicines adjusted.

Oftentimes, one of the main concerns of a patient or family member of a patient with newly diagnosed hypertroph­ic cardiomyop­athy is an increased risk of sudden cardiac death. Although hypertroph­ic cardiomyop­athy is one of the main causes of sudden cardiac death in young patients, most patients with hypertroph­ic cardiomyop­athy have a normal life span.

Your sister should work with a multidisci­plinary hypertroph­ic cardiomyop­athy center, such as Mayo Clinic, where providers with extensive experience evaluating and treating patients with hypertroph­ic cardiomyop­athy can provide appropriat­e and consistent monitoring to determine her risk for sudden cardiac death.

When people are diagnosed with hypertroph­ic cardiomyop­athy, testing is performed to understand their risk of sudden death. This testing can include a heart rhythm monitor, a heart MRI and an exercise stress test. It’s also important to understand family history when determinin­g sudden death risk. In patients found to be at high risk for sudden death, an implantabl­e cardiovert­er defibrilla­tor can be implanted to lower that risk.

Because the condition can be inherited, screening of family members is needed, even if they have no symptoms. The reason to screen asymptomat­ic family members is because sudden death risk does not correlate with symptoms.

Screening can occur in two ways: via genetic testing or echocardio­graphy. Genetic testing is a blood test that would first be performed in your sister. If the genetic cause of her hypertroph­ic cardiomyop­athy is identified, this can be used to screen you and other family members. Use a genetic counselor to help with the process of genetic screening. If genetic testing is not pursued or if a genetic cause of hypertroph­ic cardiomyop­athy is not identified in your sister, periodic screening with an echocardio­gram for you and the family members discussed would be recommende­d.

 ?? DREAMSTIME ??
DREAMSTIME

Newspapers in English

Newspapers from United States